ArticleFrontiers in pediatrics2026
Case Report: Chronic myeloid leukemia masquerading as essential thrombocythemia in a child: the imperative for early BCR::ABL1 testing in isolated thrombocytosis.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic myeloid leukemia (CML) is a rare hematologic malignancy in children, typically presenting with leukocytosis in the peripheral blood, and often accompanied by symptoms such as fever or splenomegaly. This report describes a rare pediatric case of CML that manifested solely as isolated thrombocytosis. Due to this atypical presentation, the patient was initially misdiagnosed with essential thrombocythemia (ET) and treated with hydroxyurea and aspirin, which yielded no clinical response. The diagnosis of CML was subsequently confirmed by detection of the BCR::ABL1 fusion gene. Upon confirmation, the patient was promptly initiated on imatinib therapy and achieved a complete cytogenetic response within 4 months. We also conducted a literature review of similar cases, discussing their prognosis and differential diagnosis with ET, and recommend early BCR::ABL1 fusion gene testing in all pediatric patients presenting with isolated thrombocytosis to ensure accurate diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.